---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-122387"
form_type: "8-K"
ticker: "IBIO"
cik: "0001420720"
company_name: "iBio, Inc."
filed_at: "2024-11-25T23:59:59+00:00"
generated_at: "2026-05-29T18:47:23.203572+00:00"
event_type: "leadership"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# iBio appoints David Arkowitz and António Parada as independent directors

## Summary
- David Arkowitz (Alkeus Pharma CFO) and António Parada (FairJourney Biologics CEO) join board effective Nov 25, 2024.
- Arkowitz brings financial expertise; Parada adds antibody discovery depth; CEO cites alignment with next-gen strategy.
- Departing director General Tom Hill thanked for 16 years of service; board now three Class I directors.
- Annual meeting on Nov 21 passed all proposals: elected three directors, ratified Grassi & Co., and approved say-on-pay.

## SEC filing metadata
- accession: 0001104659-24-122387
- form_type: 8-K
- ticker: IBIO
- cik: 0001420720
- company_name: iBio, Inc.
- filed_at: 2024-11-25T23:59:59+00:00
- event_type: leadership
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420720/000110465924122387/0001104659-24-122387-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420720/000110465924122387/tm2429233d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-122387
- JSON: https://secwatch.observer/filing/0001104659-24-122387.json
- Plain text: https://secwatch.observer/filing/0001104659-24-122387.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.